Analysis of disease burden of skin malignant melanoma in China_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Yan , XIAO Shengxiang ,  ZHANG Yanfei

Department of Dermatology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, P. R. China;

Corresponding author：

ZHANG Yanfei, Email: zhangyanfei723@.163.com

Keywords：

GBD 2019; China; Skin malignant melanoma; Burden

DOI：

10.7507/1672-2531.202201038

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the epidemiological burden and trend of skin malignant melanoma in China based on the data from the global burden of disease 2019 (GBD 2019). Methods The data about quantity of incidences/illnesses/deaths, age-standardized incidence/prevalence rates/mortality, disability-adjusted life years (DALYs), and DALY rate of skin malignant melanoma in China from 1990 to 2019 were obtained from the GBD 2019 databases. The epidemiological trends, age-period-cohort trends, and the relationship between the incidence and sociodemographic index (SDI) were analyzed.Results In 2019, both prevalence and incidence of skin malignant melanoma in China were at low levels in the world, the age-standardized mortality ranked the 35th in the 204 countries GBD researched, the number of prevalent cases and incident cases increased compared with 1990 (12.65% and 3.57%, respectively), the prevalence and incidence rates showed growth trends, while the DALY rate and mortality decreased slowly. The prevalence of skin malignant melanoma peaked age at 50 to 54 years old. The incidence peak age of males was older than that of females (55-59 years old for males vs. 50-54 years old for females), while the mortality peak age of males was younger than that of females (55-59 years old for males vs. 75-79 years old for females). With the increasing of SDI value, the incidence of skin malignant melanoma showed a linear growth trend. DALY rate was negatively correlated with SDI (P<0.05). Conclusion From 1990 to 2019, age-standardized incidence and prevalence of skin malignant melanoma in China are increasing, while DALY rate and mortality are decreasing, and these are correlated with social and medical development.

Citation： WANG Yan, XIAO Shengxiang, ZHANG Yanfei. Analysis of disease burden of skin malignant melanoma in China. Chinese Journal of Evidence-Based Medicine, 2022, 22(5): 524-529. doi: 10.7507/1672-2531.202201038 Copy

1.	Guy GP Jr, Thomas CC, Thompson T, et al. Vital signs: Melanoma incidence and mortality trends and projections - United States, 1982–2030. Morb Mortal Wkly Rep, 2015, 64(21): 591-596.
2.	Guy GP, Machlin SR, Ekwueme DU, et al. Prevalence and costs of skin cancer treatment in the U. S. , 2002-2006 and 2007-2011. Am J Prev Med, 2015, 48(2): 183-187.
3.	Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol, 2014, 134(6): 1527-1534.
4.	Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol, 2006, 55(5): 741-760.
5.	The Skin Cancer Foundation. Skin cancer facts & statistics, 2020. Available at: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts.
6.	Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature, 2007, 445(7130): 851-857.
7.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
8.	GBD 2017 Population and Fertility collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2018, 392(10159): 1995-2051.
9.	GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet, 2017, 390(10100): 1260-1344.
10.	石菊芳, 张玥, 曲春枫, 等. 以伤残调整生命年为指标的中国人群癌症疾病负担现状. 中华预防医学杂志, 2015, (4): 365-369.
11.	Sean M. A new way to measure progress in global health-Humanosphere, 2020. Available at: http://www.humanosphere.org/global-health/2016/10/a-new-way-to-measure-progress-global-health.
12.	GBD 2015 Healthcare Access and Quality Collaborators. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the global burden of disease study 2015. Lancet, 2017, 390(10091): 231-266.
13.	GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2018, 392(10159): 1736-1788.
14.	屈彦, 王天一, 杨津, 等. GBD数据库的数据提取方法与流程. 中国循证心血管医学杂志, 2019, 11(9): 1043-1046.
15.	Runkle GP, Zaloznik AJ. Malignant melanoma. Am Fam Physician, 1994, 49(1): 91-98.
16.	National Cancer Institute. Cancer stat facts: melanoma of the skin, 2021. Available at: https://seer.cancer.gov/statfacts/html/melan.html.
17.	Centers for Disease Control and Prevention. Melanoma of the skin statistics, 2021. Available at: https://www.cdc.gov/cancer/skin/statistics/index.htm.
18.	Yu J, Luo X, Huang H, et al. Clinical characteristics of malignant melanoma in southwest china: a single-center series of 82 consecutive cases and a meta-analysis of 958 reported cases. PLoS One, 2016, 11(11): e0165591.
19.	Brożyna AA, Jóźwicki W, Roszkowski K, et al. Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget, 2016, 7(14): 17844-17853.
20.	Hao M, Zhao G, Du X, et al. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. Tumour Biol, 2016, 37(8): 10339-10348.
21.	Beasley G, Tyler D. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol, 2015, 22(2): 358-360.
22.	American Cancer Society. Cancer facts and figures, 2021. Available at:https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures.html.
23.	Watts CG, Cust AE, Menzies SW, et al. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic. JAMA Dermatol, 2015, 151(2): 178-186.
24.	Ossio R, Roldán-Marín R, Martínez-Said H, et al. Melanoma: a global perspective. Nat Rev Cancer, 2017, 17(7): 393-394.
25.	Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol, 2015, 172(4): 885-915.

1. Guy GP Jr, Thomas CC, Thompson T, et al. Vital signs: Melanoma incidence and mortality trends and projections - United States, 1982–2030. Morb Mortal Wkly Rep, 2015, 64(21): 591-596.
2. Guy GP, Machlin SR, Ekwueme DU, et al. Prevalence and costs of skin cancer treatment in the U. S. , 2002-2006 and 2007-2011. Am J Prev Med, 2015, 48(2): 183-187.
3. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol, 2014, 134(6): 1527-1534.
4. Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol, 2006, 55(5): 741-760.
5. The Skin Cancer Foundation. Skin cancer facts & statistics, 2020. Available at: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts.
6. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature, 2007, 445(7130): 851-857.
7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
8. GBD 2017 Population and Fertility collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2018, 392(10159): 1995-2051.
9. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet, 2017, 390(10100): 1260-1344.
10. 石菊芳, 张玥, 曲春枫, 等. 以伤残调整生命年为指标的中国人群癌症疾病负担现状. 中华预防医学杂志, 2015, (4): 365-369.
11. Sean M. A new way to measure progress in global health-Humanosphere, 2020. Available at: http://www.humanosphere.org/global-health/2016/10/a-new-way-to-measure-progress-global-health.
12. GBD 2015 Healthcare Access and Quality Collaborators. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the global burden of disease study 2015. Lancet, 2017, 390(10091): 231-266.
13. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2018, 392(10159): 1736-1788.
14. 屈彦, 王天一, 杨津, 等. GBD数据库的数据提取方法与流程. 中国循证心血管医学杂志, 2019, 11(9): 1043-1046.
15. Runkle GP, Zaloznik AJ. Malignant melanoma. Am Fam Physician, 1994, 49(1): 91-98.
16. National Cancer Institute. Cancer stat facts: melanoma of the skin, 2021. Available at: https://seer.cancer.gov/statfacts/html/melan.html.
17. Centers for Disease Control and Prevention. Melanoma of the skin statistics, 2021. Available at: https://www.cdc.gov/cancer/skin/statistics/index.htm.
18. Yu J, Luo X, Huang H, et al. Clinical characteristics of malignant melanoma in southwest china: a single-center series of 82 consecutive cases and a meta-analysis of 958 reported cases. PLoS One, 2016, 11(11): e0165591.
19. Brożyna AA, Jóźwicki W, Roszkowski K, et al. Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget, 2016, 7(14): 17844-17853.
20. Hao M, Zhao G, Du X, et al. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. Tumour Biol, 2016, 37(8): 10339-10348.
21. Beasley G, Tyler D. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol, 2015, 22(2): 358-360.
22. American Cancer Society. Cancer facts and figures, 2021. Available at:https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures.html.
23. Watts CG, Cust AE, Menzies SW, et al. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic. JAMA Dermatol, 2015, 151(2): 178-186.
24. Ossio R, Roldán-Marín R, Martínez-Said H, et al. Melanoma: a global perspective. Nat Rev Cancer, 2017, 17(7): 393-394.
25. Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol, 2015, 172(4): 885-915.

Chinese Journal of Evidence-Based Medicine

Analysis of disease burden of skin malignant melanoma in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content